Though the country is 10x's second-biggest market outside North America, after China, several Wall Street analysts said 10x's development of Next GEM tech would help limit the fallout from the decision. Germany is just one of several fronts in an ongoing intellectual property battle between Bio-Rad and 10x. 4, 2018, to cancel the utility model, but those proceedings have not yet been scheduled. 28, 2018 and May 14, 2019.ġ0x said it filed an action with the German Patent and Trademark office on Sept. 13, 2018, alleging infringement of the utility model. Bio-Rad initially sued 10x in the Munich court on Feb. It usually offers a shorter term of protection and protects only products, not methods or processes. However, until 10x converts its Linked-Read sequencing and Single Cell CNV kits to Next GEM Chips, customers in Germany will not be able to purchase those products.Ī utility model is a type of intellectual property similar to a patent, though there is no examination of novelty, inventive step, or industrial applications during the application process. " As most of our German customers have already transitioned to Next GEM, we believe that disruption to ongoing research will be minimal," the 10x spokesperson added. "The Court's ruling did not address the company's Next GEM products, which were not accused in this action and which constitute the majority of the company's sales in Germany," 10x said in the filing. "Since we sell 100 percent direct in Germany, this has no impact on us," the spokesperson said. The injunction also prohibits the import of those products to Germany.Ī spokesperson for 10x said the firm plans to appeal and added that it believes it will not have to recall its legacy products. The court said 10x must compensate Bio-Rad for "unspecified damages" and must recall the products from distribution channels in Germany. ![]() DE 20 2011 110 979, held by Bio-Rad Laboratories. 20, along with a ruling that those products had infringed German Utility Model No. NEW YORK – A German regional court last week issued an injunction, preventing 10x Genomics from selling its older GEM microfluidic chips, certain of its Chromium Controller instruments, and certain accessories in that country.Īccording to a filing by 10x with the US Securities and Exchange Commission today, the Munich regional court issued the injunction Nov. This story has been updated to include comments from 10x Genomics. Advances in Clinical Genomics Profiling.Please see our CSCI Flow Cytometry 10x Genomics Service document for more pricing and more details. ![]() ![]() Users must complete comprehensive training with CSCI Flow Cytometry staff before being granted access to the Chromium Control and workspace.Researchers whose needs are infrequent are encouraged to utilize the SCC's full-service option. The service is recommended for researchers who require off-hours access to the Chromium Controller and plan to use the technology regularly. 10x Genomics access is offered on a self-use basis only.Users can obtain 10x Next GEM reagents from the SCC when using the core's library preparation and sequencing services.Library preparation and sequencing must be arranged with the SCC or independently by researchers. CSCI Flow Cytometry supports only the GEM-capture and cDNA barcoding steps.Users also have the option to perform library preparation and arrange for sequencing independently. Barcoded cDNA can then be taken to the SCC for library preparation or sequencing. The Columbia Stem Cell Initiative Flow Cytometry core, in collaboration with the Columbia Genome Center Single CellĪnalysis Core (SCC) is pleased to offer access to 10x Genomics single-cell technology.Īfter obtaining reagents from the Single Cell Analysis core, fully-trained users have independent access to the 10x Genomics Chromium Controller, workspace, and associated equipment for the generation of barcoded cDNA from GEM-captured cells.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |